ArticleClinical genitourinary cancer2022

Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.

Dylan J Martini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.